AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A method for preventing and/or treating a neurodegenerative disease, neuropathy or a disease whose treatment requires neural regeneration, which comprises ~~parenteral administration of~~ parenterally administering to a mammal an effective amount of (2R)-2-propyloctanoic acid or a salt thereof ~~to a mammal~~.

2. (Original) The method according to claim 1, wherein the disease to be treated is neurodegenerative disease.

3. (Original) The method according to claim 1, wherein the amount per dose in the parenteral administration is within a range of about 100 mg to about 2,000 mg.

4. (Original) The method according to claim 2, wherein the neurodegenerative disease is stroke.

5. (Original) The method according to claim 2, wherein the neurodegenerative disease is cerebral infarction.

6. (Original) The method according to claim 1, wherein the parenteral administration is intravenous administration.

7. (Original) The method according to claim 6, wherein the intravenous administration is continuous administration.

8. (Original) The method according to claim 7, wherein the continuous administration is infusion bag administration.

9. (Original) The method according to claim 1, wherein the dose of parenteral administration per once a day during an administration period of 1 day to 100 days is within a range of about 100 mg to about 2,000 mg.

10. (Original) The method according to claim 9, wherein the administration period is from 1 day to 10 days.

11. (Original) The method according to claim 10, wherein the administration period is 3 days, 4 days, 5 days, 6 days or 7 days.

12. (Original) The method according to claim 11, wherein the administration period is 7 days.

13. (Original) The method according to claim 1, wherein the dose per 1 kg of body weight of a patient is within a range of about 2 mg to about 12 mg.

14. (Original) The method according to claim 13, wherein the dose per 1 kg of body weight of a patient is about 2 mg, about 4 mg, about 6 mg, about 8 mg, about 10 mg or about 12 mg.

15. (Original) The method according to claim 14, wherein the dose per 1 kg of body weight of a patient is about 4 mg or about 8 mg.

16. (Original) The method according to claim 1, which is a method for inhibition of S-100β increase.

17. (Original) A method for inhibition of S-100β increase, which comprises parenterally administering to a mammal an effective amount of (2R)-2-propyloctanoic acid or a salt thereof.

18. (Original) The method according to claim 17, wherein the amount per dose in the parenteral administration is within a range of about 100 mg to about 2,000 mg.

19. (Original) The method according to claim 17, wherein the parenteral administration is intravenous administration.

20. (Original) The method according to claim 17, wherein the dose of parenteral administration per once a day during an administration period of 1 day to 100 days is within a range of about 100 mg to about 2,000 mg.

21. (Original) The method according to claim 17, wherein the dose per 1 kg of body weight of a patient is within a range of about 2 mg to about 12 mg.

Claims 22-23. (Canceled)

24. (Original) A method for preventing and/or treating cerebral infarction which comprises parenterally administering to a mammal an effective amount of (2R)-2-propyloctanoic acid or a salt thereof in combination with an effective amount of a tissue plasminogen activator.

25. (Original) The method according to claim 24, wherein the dose of (2R)-2-propyloctanoic acid or a salt thereof per 1 kg of body weight of a patient is about 4 mg or about 8 mg, and the dose of the tissue plasminogen activator per 1 kg of body weight of a patient is about 0.6 mg or about 0.9 mg.

26. (Original) The method according to claim 25, wherein the administration is started within 3 hours after onset of the cerebral infarction.

27. (Currently Amended) A parenterally administered ~~agent~~ composition for preventing and/or treating cerebral infarction which comprises (2R)-2-propyloctanoic acid or a salt thereof in combination with a tissue plasminogen activator.

Claim 28. (Canceled)

29. (Currently Amended) The method according to claim 1, ~~17 or 24,~~ wherein (2R)-2-propyloctanoic acid is used.

30. (Currently Amended) The ~~agent~~ composition according to claim ~~22 or~~ 27, wherein (2R)-2-propyloctanoic acid is comprised.

Claim 31. (Canceled)

32. (Currently Amended) A method for treating cerebral infarction, which comprises ~~continuous administration of~~ continuously administering to a mammal intravenously (2R)-2-propyloctanoic acid ~~intravenously~~ using an infusion bag at a dose of about 4 mg or about 8 mg per 1 kg of body weight during administration period for 7 days.

33. (New) The method according to claim 17, wherein (2R)-2-propyloctanoic acid is used.

34. (New) The method according to claim 24, wherein (2R)-2-propyloctanoic acid is used.